MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Viatris Inc.
VTRS Details
Viatris Inc. (NASDAQ: VTRS) is a healthcare company that specializes on providing medicines and long-term therapies to patients in over 165 countries. Its portfolio is diversified into Brands, Complex Generics and Biosimilars, and Generic divisions, contains approximately 1,400 authorized compounds across a variety of therapeutic areas that tackle both communicable and non-communicable disorders. VTRS was established in November 2020 when Mylan N.V. and the Upjohn business (formerly part of Pfizer Inc.) merged, and it went public on the NASDAQ on November 17, 2020.
Latest News:
Q3FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/Sales-Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
VTRS' stock price has increased 3.11% in the past six months and is currently trading close to the mid-band of its 52-week range of USD 11.96 to USD 18.68. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 16.91.
Considering the slight movement in the stock price in the past six months, decent balance sheet, robust dividend yield, recent FDA approval, solid margins, current valuation, and associated risks, we recommend a "Hold" rating on the stock at the current price of USD 15.25, down 0.46%, as of February 16, 2022.
Three-Year Technical Price Chart (as on February 16, 2022). Source: REFINITIV, Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.